3,6-Dichloro-benzo[b]thiophene-2-carboxylic acid

Product Name3,6-Dichloro-benzo[b]thiophene-2-carboxylic acid
CAS34576-94-8
MFC9H4Cl2O2S
MW247.1
EINECS
MOL File34576-94-8.mol

Chemical Properties

Boiling point	426.4±40.0 °C(Predicted)
Density	1.653±0.06 g/cm3(Predicted)
storage temp.	2-8°C
solubility	Soluble in DMSO (up to at least 20 mg/ml)
form	solid
pka	2.09±0.30(Predicted)
color	Off-white
Stability	Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
InChI	1S/C9H4Cl2O2S/c10-4-1-2-5-6(3-4)14-8(7(5)11)9(12)13/h1-3H,(H,12,13)
InChIKey	AAHPIJMQJAZYTM-UHFFFAOYSA-N
SMILES	[s]1c2c(c(c1C(=O)O)Cl)ccc(c2)Cl

Safety Information

WGK Germany	WGK 3
Storage Class	11 - Combustible Solids

Usage And Synthesis

Description

3,6-dichloro-benzo[b]thiophene-2-Carboxylic acid is an inhibitor of myeloid cell leukemia 1 (Mcl-1) with a K_i value of 59 μM for binding of FITC-Mcl-1-BH2 peptide binding to Mcl-1. It has been used as a building block in the synthesis of inhibitors of Mcl-1, the toll-like receptor 3/double-stranded RNA (TLR3/dsRNA) complex, and D-amino acid oxidase (DAO).

Uses

BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC)[1]. BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM[2].

in vivo

BT2 (20 mg/kg/day; intraperitoneal injection; daily; for 7 days; C57BL/6J male mice) treatment robustly enhances BCKDC activity in the heart (12.3-fold) compared with the vehicle-treated animals. Less activation is obtained in muscle and kidney at 3.6- and 3.8-fold, respectively. The -fold activation of BCKDC activity in the above tissues correlates with decreased phosphorylation in heart, muscle, and kidney after the long term BT2 treatment. BT2 treatment reduces the protein levels of BDK in kidneys and heart^[1].

Animal Model:	C57BL/6J male mice (8-10-week-old)^[1]
Dosage:	20 mg/kg/day
Administration:	Intraperitoneal injection; daily; for 1 week
Result:	BCKDC activity was robustly (12.3-fold) enhanced in the heart compared with the vehicle-treated animals. Less activation was obtained in muscle and kidney at 3.6- and 3.8-fold, respectively. The protein levels of BDK in kidneys and heart were reduced to averages of 39 and 24%, respectively.

IC 50

BDK: 3.19 μM (IC₅₀); Mcl-1: 59 μM (Ki)

References

[1] SHIH-CHIA TSO. Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase.[J]. The Journal of Biological Chemistry, 2014, 289 30: 20583-20593. DOI:10.1074/jbc.m114.569251
[2] ANDERS FRIBERG. Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design[J]. Journal of Medicinal Chemistry, 2012, 56 1: 15-30. DOI:10.1021/jm301448p

3,6-Dichloro-benzo[b]thiophene-2-carboxylic acid Supplier

3,6-Dichloro-benzo[b]thiophene-2-carboxylic acid manufacturers

Related Product Information

Send Inquriy